Theravance Biopharma TBPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.93M-108% | $61.02M+1,588% | $3.62M-93.4% | $54.84M+504% | -$13.58M+12.5% | ||
| $381K-4.5% | $399K-1.5% | $405K-1.0% | $409K-1.0% | $413K-2.1% | ||
| $4.5M+0.5% | $4.48M-2.1% | $4.58M+0.7% | $4.54M-6.8% | $4.88M-16.3% | ||
| $73.28M— | —— | —— | $208.07M+383% | $43.04M+4,872% | ||
| $52.59M— | $0+100% | -$100.25M-176% | -$36.26M-218% | $30.63M+95.3% | ||
| -$5.58M-274% | -$1.49M-273% | -$400K+20.5% | -$503K+41.1% | -$854K-134% | ||
| $120.3M— | —— | —— | $171.31M+135% | $72.82M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
